Results 41 to 50 of about 19,745 (243)

Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches

European Journal of Immunology, Volume 53, Issue 1, January 2023., 2023
B lineage cells have been identified as therapeutic targets in autoimmune diseases. In the current review article, we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with a focus on inflammatory rheumatic diseases.
Ana Merino‐Vico, Giulia Frazzei, Jan Piet van Hamburg, Sander W. Tas   +3 more
wiley   +1 more source

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Life, 2021
Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf   +2 more
doaj   +1 more source

xTrimoABFold: De novo Antibody Structure Prediction without MSA [PDF]

arXiv, 2022
In the field of antibody engineering, an essential task is to design a novel antibody whose paratopes bind to a specific antigen with correct epitopes. Understanding antibody structure and its paratope can facilitate a mechanistic understanding of its function.
arxiv  

Chemical generation of bispecific antibodies [PDF]

Proceedings of the National Academy of Sciences, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang, Bryan Oates, Curt W. Bradshaw, Michael J. Shields, Bin Liu, Richard A. Lerner, Joselyn Del Rosario, Crystal Hagen, Dingguo Liu, Lingna Li, Ping Jin, Michelle Parish, Robert E. Murphy, Gary Woodnutt, Jing-Yu Lai, Joel Desharnais, Marla J. Matin, Zemeda W Ainekulu, Abhijit Bhat, Nancy Levin, Venkata Doppalapudi, Rodney W. Lappe   +21 more
openaire   +3 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

On Pre-trained Language Models for Antibody [PDF]

arXiv, 2023
Antibodies are vital proteins offering robust protection for the human body from pathogens. The development of general protein and antibody-specific pre-trained language models both facilitate antibody prediction tasks. However, there have been limited studies that comprehensively explore the representation capability of distinct pre-trained language ...
arxiv  

CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

FEBS Open Bio, EarlyView.
Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano, Kouki Okita, Shogo Okazaki, Soshi Yoshimoto, Sachiko Masuko, Hideki Yagi, Kazunori Kato, Yoshihisa Tomioka, Kenichi Imai, Yoichi Hamada, Kazue Masuko, Kayoko Shimada‐Takaura, Noriaki Nagai, Hideyuki Saya, Tomio Arai, Toshiyuki Ishiwata, Takashi Masuko   +16 more
wiley   +1 more source

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

Global Challenges, Volume 7, Issue 1, January 2023., 2023
Combining oncolytic viruses with anti‐checkpoint antibodies such as anti‐PD‐1, anti‐PDL‐1, and anti‐CTLA4 or CAR‐T cells can be effective in cancer therapy in a synergistic fashion. Oncolytic virotherapy induces the expression of PD‐1 and PDL‐1 in the tumor microenvironment components. Virotherapy promotes the infiltration of CD4+ and CD8+ T cells into
Hai Zou, Xiao‐Zhou Mou, Biao Zhu
wiley   +1 more source

Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection

Frontiers in Immunology, 2022
A subset of antibodies found in cattle comprises ultralong CDR-H3 regions of up to 70 amino acids. Interestingly, this type of immunoglobulin usually pairs with the single germline VL gene, V30 that is typically very conserved in sequence.
Daniel Klewinghaus, Lukas Pekar, Paul Arras, Simon Krah, Bernhard Valldorf, Harald Kolmar, Stefan Zielonka   +6 more
doaj   +1 more source

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

Advanced Materials, EarlyView.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu, Won Joon Kim, Hyunjin Lee, Xiaoping Bao, Pilnam Kim   +4 more
wiley   +1 more source